Allergan PLC (AGN)

• Annual Data
• Quarterly Data

Allergan PLC, Consolidated Statement of Financial Position, Assets

USD $ in thousands

Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18), 10-K (filing date: 2014-02-25).

---

Assets, Selected Items

Item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Allergan PLC’s current assets increased from 2015 to 2016 but then slightly declined from 2016 to 2017 not reaching 2015 level.
Property, plant and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Allergan PLC’s property, plant and equipment, net increased from 2015 to 2016 and from 2016 to 2017.
Non current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Allergan PLC’s non current assets declined from 2015 to 2016 and from 2016 to 2017.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Allergan PLC’s total assets declined from 2015 to 2016 and from 2016 to 2017.

---

Current Assets, Selected Items

Item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Allergan PLC’s cash and cash equivalents increased from 2015 to 2016 and from 2016 to 2017.
Marketable securities	Amount of investment in marketable security, classified as current.	Allergan PLC’s marketable securities increased from 2015 to 2016 but then slightly declined from 2016 to 2017 not reaching 2015 level.
Accounts receivable, net	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Allergan PLC’s accounts receivable, net increased from 2015 to 2016 and from 2016 to 2017.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Allergan PLC’s inventories declined from 2015 to 2016 but then increased from 2016 to 2017 not reaching 2015 level.